Intensive voice treatment (LSVT®) for patients with Parkinson's disease: a 2 year follow up
Identifieur interne : 000B95 ( Main/Corpus ); précédent : 000B94; suivant : 000B96Intensive voice treatment (LSVT®) for patients with Parkinson's disease: a 2 year follow up
Auteurs : L O Ramig ; S. Sapir ; S. Countryman ; A A Pawlas ; C. O'Brien ; M. Hoehn ; L L ThompsonSource :
- Journal of Neurology, Neurosurgery & Psychiatry [ 0022-3050 ] ; 2001-10-01.
Abstract
OBJECTIVES To assess long term (24 months) effects of the Lee Silverman voice treatment (LSVT®), a method designed to improve vocal function in patients with Parkinson's disease. METHODS Thirty three patients with idiopathic Parkinson's disease were stratified and randomly assigned to two treatment groups. One group received the LSVT®, which emphasises high phonatory-respiratory effort. The other group received respiratory therapy (RET), which emphasises high respiratory effort alone. Patients in both treatment groups sustained vowel phonation, read a passage, and produced a monologue under identical conditions before, immediately after, and 24 months after speech treatment. Change in vocal function was measured by means of acoustic analyses of voice loudness (measured as sound pressure level, or SPL) and inflection in voice fundamental frequency (measured in terms of semitone standard deviation, or STSD). RESULTS The LSVT® was significantly more effective than the RET in improving (increasing) SPL and STSD immediately post-treatment and maintaining those improvements at 2 year follow up. CONCLUSIONS The findings provide evidence for the efficacy of the LSVT® as well as the long term maintenance of these effects in the treatment of voice and speech disorders in patients with idiopathic Parkinson's disease.
Url:
DOI: 10.1136/jnnp.71.4.493
Links to Exploration step
ISTEX:5CB6FCB786207A62AA94D28C7721596D39781D38Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Intensive voice treatment (LSVT®) for patients with Parkinson's disease: a 2 year follow up</title><author><name sortKey="Ramig, L O" sort="Ramig, L O" uniqKey="Ramig L" first="L O" last="Ramig">L O Ramig</name><affiliation><mods:affiliation></mods:affiliation></affiliation></author><author><name sortKey="Sapir, S" sort="Sapir, S" uniqKey="Sapir S" first="S" last="Sapir">S. Sapir</name><affiliation><mods:affiliation></mods:affiliation></affiliation></author><author><name sortKey="Countryman, S" sort="Countryman, S" uniqKey="Countryman S" first="S" last="Countryman">S. Countryman</name><affiliation><mods:affiliation></mods:affiliation></affiliation></author><author><name sortKey="Pawlas, A A" sort="Pawlas, A A" uniqKey="Pawlas A" first="A A" last="Pawlas">A A Pawlas</name><affiliation><mods:affiliation></mods:affiliation></affiliation></author><author><name sortKey="O Brien, C" sort="O Brien, C" uniqKey="O Brien C" first="C" last="O'Brien">C. O'Brien</name><affiliation><mods:affiliation></mods:affiliation></affiliation></author><author><name sortKey="Hoehn, M" sort="Hoehn, M" uniqKey="Hoehn M" first="M" last="Hoehn">M. Hoehn</name><affiliation><mods:affiliation></mods:affiliation></affiliation></author><author><name sortKey="Thompson, L L" sort="Thompson, L L" uniqKey="Thompson L" first="L L" last="Thompson">L L Thompson</name><affiliation><mods:affiliation></mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:5CB6FCB786207A62AA94D28C7721596D39781D38</idno><date when="2001" year="2001">2001</date><idno type="doi">10.1136/jnnp.71.4.493</idno><idno type="url">https://api.istex.fr/document/5CB6FCB786207A62AA94D28C7721596D39781D38/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000B95</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Intensive voice treatment (LSVT®) for patients with Parkinson's disease: a 2 year follow up</title><author><name sortKey="Ramig, L O" sort="Ramig, L O" uniqKey="Ramig L" first="L O" last="Ramig">L O Ramig</name><affiliation><mods:affiliation></mods:affiliation></affiliation></author><author><name sortKey="Sapir, S" sort="Sapir, S" uniqKey="Sapir S" first="S" last="Sapir">S. Sapir</name><affiliation><mods:affiliation></mods:affiliation></affiliation></author><author><name sortKey="Countryman, S" sort="Countryman, S" uniqKey="Countryman S" first="S" last="Countryman">S. Countryman</name><affiliation><mods:affiliation></mods:affiliation></affiliation></author><author><name sortKey="Pawlas, A A" sort="Pawlas, A A" uniqKey="Pawlas A" first="A A" last="Pawlas">A A Pawlas</name><affiliation><mods:affiliation></mods:affiliation></affiliation></author><author><name sortKey="O Brien, C" sort="O Brien, C" uniqKey="O Brien C" first="C" last="O'Brien">C. O'Brien</name><affiliation><mods:affiliation></mods:affiliation></affiliation></author><author><name sortKey="Hoehn, M" sort="Hoehn, M" uniqKey="Hoehn M" first="M" last="Hoehn">M. Hoehn</name><affiliation><mods:affiliation></mods:affiliation></affiliation></author><author><name sortKey="Thompson, L L" sort="Thompson, L L" uniqKey="Thompson L" first="L L" last="Thompson">L L Thompson</name><affiliation><mods:affiliation></mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Journal of Neurology, Neurosurgery & Psychiatry</title><title level="j" type="abbrev">J Neurol Neurosurg Psychiatry</title><idno type="ISSN">0022-3050</idno><idno type="eISSN">1468-330X</idno><imprint><publisher>BMJ Publishing Group Ltd</publisher><date type="published" when="2001-10-01">2001-10-01</date><biblScope unit="volume">71</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="493">493</biblScope></imprint><idno type="ISSN">0022-3050</idno></series><idno type="istex">5CB6FCB786207A62AA94D28C7721596D39781D38</idno><idno type="DOI">10.1136/jnnp.71.4.493</idno><idno type="href">jnnp-71-493.pdf</idno><idno type="PMID">11561033</idno><idno type="local">jnnp;71/4/493</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0022-3050</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">OBJECTIVES To assess long term (24 months) effects of the Lee Silverman voice treatment (LSVT®), a method designed to improve vocal function in patients with Parkinson's disease. METHODS Thirty three patients with idiopathic Parkinson's disease were stratified and randomly assigned to two treatment groups. One group received the LSVT®, which emphasises high phonatory-respiratory effort. The other group received respiratory therapy (RET), which emphasises high respiratory effort alone. Patients in both treatment groups sustained vowel phonation, read a passage, and produced a monologue under identical conditions before, immediately after, and 24 months after speech treatment. Change in vocal function was measured by means of acoustic analyses of voice loudness (measured as sound pressure level, or SPL) and inflection in voice fundamental frequency (measured in terms of semitone standard deviation, or STSD). RESULTS The LSVT® was significantly more effective than the RET in improving (increasing) SPL and STSD immediately post-treatment and maintaining those improvements at 2 year follow up. CONCLUSIONS The findings provide evidence for the efficacy of the LSVT® as well as the long term maintenance of these effects in the treatment of voice and speech disorders in patients with idiopathic Parkinson's disease.</div></front></TEI><istex><corpusName>bmj</corpusName><author><json:item><name>L O Ramig</name><affiliations><json:null></json:null></affiliations></json:item><json:item><name>S Sapir</name><affiliations><json:null></json:null></affiliations></json:item><json:item><name>S Countryman</name><affiliations><json:null></json:null></affiliations></json:item><json:item><name>A A Pawlas</name><affiliations><json:null></json:null></affiliations></json:item><json:item><name>C O'Brien</name><affiliations><json:null></json:null></affiliations></json:item><json:item><name>M Hoehn</name><affiliations><json:null></json:null></affiliations></json:item><json:item><name>L L Thompson</name><affiliations><json:null></json:null></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Paper</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Drugs: CNS (not psychiatric)</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>voice treatment</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>efficacy</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item></subject><language><json:string>eng</json:string></language><abstract>OBJECTIVES To assess long term (24 months) effects of the Lee Silverman voice treatment (LSVT®), a method designed to improve vocal function in patients with Parkinson's disease. METHODS Thirty three patients with idiopathic Parkinson's disease were stratified and randomly assigned to two treatment groups. One group received the LSVT®, which emphasises high phonatory-respiratory effort. The other group received respiratory therapy (RET), which emphasises high respiratory effort alone. Patients in both treatment groups sustained vowel phonation, read a passage, and produced a monologue under identical conditions before, immediately after, and 24 months after speech treatment. Change in vocal function was measured by means of acoustic analyses of voice loudness (measured as sound pressure level, or SPL) and inflection in voice fundamental frequency (measured in terms of semitone standard deviation, or STSD). RESULTS The LSVT® was significantly more effective than the RET in improving (increasing) SPL and STSD immediately post-treatment and maintaining those improvements at 2 year follow up. CONCLUSIONS The findings provide evidence for the efficacy of the LSVT® as well as the long term maintenance of these effects in the treatment of voice and speech disorders in patients with idiopathic Parkinson's disease.</abstract><qualityIndicators><score>6.767</score><pdfVersion>1.1</pdfVersion><pdfPageSize>612 x 792 pts (letter)</pdfPageSize><refBibsNative>false</refBibsNative><keywordCount>6</keywordCount><abstractCharCount>1327</abstractCharCount><pdfWordCount>4463</pdfWordCount><pdfCharCount>30767</pdfCharCount><pdfPageCount>6</pdfPageCount><abstractWordCount>192</abstractWordCount></qualityIndicators><title>Intensive voice treatment (LSVT®) for patients with Parkinson's disease: a 2 year follow up</title><pmid><json:string>11561033</json:string></pmid><genre><json:string>research-article</json:string></genre><host><volume>71</volume><pages><first>493</first></pages><issn><json:string>0022-3050</json:string></issn><issue>4</issue><genre></genre><language><json:string>unknown</json:string></language><eissn><json:string>1468-330X</json:string></eissn><title>Journal of Neurology, Neurosurgery & Psychiatry</title></host><publicationDate>2001</publicationDate><copyrightDate>2001</copyrightDate><doi><json:string>10.1136/jnnp.71.4.493</json:string></doi><id>5CB6FCB786207A62AA94D28C7721596D39781D38</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/5CB6FCB786207A62AA94D28C7721596D39781D38/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/5CB6FCB786207A62AA94D28C7721596D39781D38/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/5CB6FCB786207A62AA94D28C7721596D39781D38/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Intensive voice treatment (LSVT®) for patients with Parkinson's disease: a 2 year follow up</title><respStmt xml:id="ISTEX-API" resp="Références bibliographiques récupérées via GROBID" name="ISTEX-API (INIST-CNRS)"></respStmt></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>BMJ Publishing Group Ltd</publisher><availability><p>BMJ</p></availability><date>2001-10-01</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Intensive voice treatment (LSVT®) for patients with Parkinson's disease: a 2 year follow up</title><author><persName><forename type="first">L O</forename><surname>Ramig</surname></persName><affiliation></affiliation></author><author><persName><forename type="first">S</forename><surname>Sapir</surname></persName><affiliation></affiliation></author><author><persName><forename type="first">S</forename><surname>Countryman</surname></persName><affiliation></affiliation></author><author><persName><forename type="first">A A</forename><surname>Pawlas</surname></persName><affiliation></affiliation></author><author><persName><forename type="first">C</forename><surname>O'Brien</surname></persName><affiliation></affiliation></author><author><persName><forename type="first">M</forename><surname>Hoehn</surname></persName><affiliation></affiliation></author><author><persName><forename type="first">L L</forename><surname>Thompson</surname></persName><affiliation></affiliation></author></analytic><monogr><title level="j">Journal of Neurology, Neurosurgery & Psychiatry</title><title level="j" type="abbrev">J Neurol Neurosurg Psychiatry</title><idno type="pISSN">0022-3050</idno><idno type="eISSN">1468-330X</idno><imprint><publisher>BMJ Publishing Group Ltd</publisher><date type="published" when="2001-10-01"></date><biblScope unit="volume">71</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="493">493</biblScope></imprint></monogr><idno type="istex">5CB6FCB786207A62AA94D28C7721596D39781D38</idno><idno type="DOI">10.1136/jnnp.71.4.493</idno><idno type="href">jnnp-71-493.pdf</idno><idno type="PMID">11561033</idno><idno type="local">jnnp;71/4/493</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2001-10-01</date></creation><langUsage><language ident="en">en</language></langUsage><abstract><p>OBJECTIVES To assess long term (24 months) effects of the Lee Silverman voice treatment (LSVT®), a method designed to improve vocal function in patients with Parkinson's disease. METHODS Thirty three patients with idiopathic Parkinson's disease were stratified and randomly assigned to two treatment groups. One group received the LSVT®, which emphasises high phonatory-respiratory effort. The other group received respiratory therapy (RET), which emphasises high respiratory effort alone. Patients in both treatment groups sustained vowel phonation, read a passage, and produced a monologue under identical conditions before, immediately after, and 24 months after speech treatment. Change in vocal function was measured by means of acoustic analyses of voice loudness (measured as sound pressure level, or SPL) and inflection in voice fundamental frequency (measured in terms of semitone standard deviation, or STSD). RESULTS The LSVT® was significantly more effective than the RET in improving (increasing) SPL and STSD immediately post-treatment and maintaining those improvements at 2 year follow up. CONCLUSIONS The findings provide evidence for the efficacy of the LSVT® as well as the long term maintenance of these effects in the treatment of voice and speech disorders in patients with idiopathic Parkinson's disease.</p></abstract><textClass><keywords scheme="keyword"><list><head>hwp-journal-coll</head><item><term>Drugs: CNS (not psychiatric)</term></item></list></keywords></textClass><textClass><keywords scheme="keyword"><list><head>hwp-journal-coll</head><item><term>Parkinson's disease</term></item></list></keywords></textClass><textClass><keywords scheme="keyword"><list><head>Keywords</head><item><term>voice treatment</term></item><item><term>efficacy</term></item><item><term>Parkinson's disease</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2001-10-01">Created</change><change when="2001-10-01">Published</change><change xml:id="refBibs-istex" who="#ISTEX-API" when="2016-3-14">References added</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/5CB6FCB786207A62AA94D28C7721596D39781D38/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="corpus bmj, element floats-wrap not found" wicri:toSee="no header"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="no"</istex:xmlDeclaration><istex:docType PUBLIC="-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" URI="archivearticle.dtd" name="istex:docType"></istex:docType><istex:document><article article-type="research-article" xml:lang="EN"><front><journal-meta><journal-id journal-id-type="hwp">jnnp</journal-id><journal-id journal-id-type="nlm-ta">J Neurol Neurosurg Psychiatry</journal-id><journal-id journal-id-type="publisher-id">jnnp</journal-id><journal-title>Journal of Neurology, Neurosurgery & Psychiatry</journal-title><abbrev-journal-title abbrev-type="publisher">J Neurol Neurosurg Psychiatry</abbrev-journal-title><issn pub-type="ppub">0022-3050</issn><issn pub-type="epub">1468-330X</issn><publisher><publisher-name>BMJ Publishing Group Ltd</publisher-name></publisher></journal-meta><article-meta><article-id>00153</article-id><article-id pub-id-type="other">jnnp;71/4/493</article-id><article-id pub-id-type="doi">10.1136/jnnp.71.4.493</article-id><article-id pub-id-type="pmid">11561033</article-id><article-id pub-id-type="other">493</article-id><article-id pub-id-type="other">jnnp.71.4.493</article-id><article-categories><subj-group subj-group-type="heading"><subject content-type="original">Paper</subject></subj-group><subj-group subj-group-type="hwp-journal-coll"><subject>Drugs: CNS (not psychiatric)</subject></subj-group><subj-group subj-group-type="hwp-journal-coll"><subject>Parkinson's disease</subject></subj-group></article-categories><title-group><article-title>Intensive voice treatment (LSVT®) for patients with Parkinson's disease: a 2 year follow up</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Ramig</surname><given-names>L O</given-names></name><xref rid="tO1001" ref-type="aff">a</xref><xref rid="tO1002" ref-type="aff">b</xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Sapir</surname><given-names>S</given-names></name><xref rid="tO1002" ref-type="aff">b</xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Countryman</surname><given-names>S</given-names></name><xref rid="tO1002" ref-type="aff">b</xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Pawlas</surname><given-names>A A</given-names></name><xref rid="tO1002" ref-type="aff">b</xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>O'Brien</surname><given-names>C</given-names></name><xref rid="tO1003" ref-type="aff">c</xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Hoehn</surname><given-names>M</given-names></name><xref rid="tO1004" ref-type="aff">d</xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Thompson</surname><given-names>L L</given-names></name><xref rid="tO1004" ref-type="aff">d</xref></contrib></contrib-group><aff id="O1001"><target id="tO1001" target-type="aff"><sup>a</sup>Department of Speech Language Hearing Sciences, University of Colorado-Boulder, Colorado, USA, </target><target id="tO1002" target-type="aff"><sup>b</sup>Wilbur James Gould Voice Center, Denver Center for the Performing Arts, 1245 Champa Street, Denver Colorado 80204, USA, </target><target id="tO1003" target-type="aff"><sup>c</sup>Colorado Neurological Institute, Englewood, Colorado, USA, </target><target id="tO1004" target-type="aff"><sup>d</sup>Department of Psychiatry, University of Colorado Health Science Center, Denver, Colorado, USA</target></aff><author-notes><corresp>Dr L O Ramig<email xlink:type="simple">ramig@spot.colorado.edu</email></corresp></author-notes><pub-date pub-type="ppub"><day>1</day><month>10</month><year>2001</year></pub-date><pub-date pub-type="epub"><day>1</day><month>10</month><year>2001</year></pub-date><volume>71</volume><volume-id pub-id-type="other">71</volume-id><volume-id pub-id-type="other">71</volume-id><issue>4</issue><issue-id pub-id-type="other">jnnp;71/4</issue-id><issue-id pub-id-type="other">4</issue-id><issue-id pub-id-type="other">71/4</issue-id><fpage>493</fpage><history><date date-type="received"><day>14</day><month>2</month><year>2000</year></date><date date-type="rev-recd"><day>11</day><month>5</month><year>2001</year></date><date date-type="accepted"><day>23</day><month>5</month><year>2001</year></date></history><permissions><copyright-statement>Journal of Neurology, Neurosurgery, and Psychiatry</copyright-statement><copyright-year>2001</copyright-year></permissions><self-uri content-type="pdf" xlink:role="full-text" xlink:href="jnnp-71-493.pdf"></self-uri><abstract><sec><title>OBJECTIVES</title><p>To assess long term (24 months) effects of the Lee Silverman voice treatment (LSVT®), a method designed to improve vocal function in patients with Parkinson's disease.</p></sec><sec sec-type="methods"><title>METHODS</title><p>Thirty three patients with idiopathic Parkinson's disease were stratified and randomly assigned to two treatment groups. One group received the LSVT®, which emphasises high phonatory-respiratory effort. The other group received respiratory therapy (RET), which emphasises high respiratory effort alone. Patients in both treatment groups sustained vowel phonation, read a passage, and produced a monologue under identical conditions before, immediately after, and 24 months after speech treatment. Change in vocal function was measured by means of acoustic analyses of voice loudness (measured as sound pressure level, or SPL) and inflection in voice fundamental frequency (measured in terms of semitone standard deviation, or STSD).</p></sec><sec><title>RESULTS</title><p>The LSVT® was significantly more effective than the RET in improving (increasing) SPL and STSD immediately post-treatment and maintaining those improvements at 2 year follow up.</p></sec><sec><title>CONCLUSIONS</title><p>The findings provide evidence for the efficacy of the LSVT® as well as the long term maintenance of these effects in the treatment of voice and speech disorders in patients with idiopathic Parkinson's disease.</p></sec></abstract><kwd-group><kwd>voice treatment</kwd><kwd>efficacy</kwd><kwd>Parkinson's disease</kwd></kwd-group></article-meta></front><floats-wrap><fig id="F1" position="float"><label>Figure 1</label><caption><p>Mean SPL of sustained “AH” immediately pretreatment (before), immediately after, and 24 months after treatment (FU) in the LSVT® and RET groups. Differences from before to immediately after and from before to FU are significant in the LSVT® group (p=0.000) but not in the RET group.</p></caption><graphic xlink:href="jnnp-71-493-F1.jpg" alt-version="no" position="float" xlink:type="simple"></graphic></fig><fig id="F2" position="float"><label>Figure 2</label><caption><p>Mean SPL of reading the “Rainbow Passage” immediately pretreatment (before), immediately post-treatment (after), and 24 months after treatment (FU) in the LSVT® and RET groups. Differences from before to immediately after and from before to FU are significant in the LSVT® group (p=0.000 and p=0.001, respectively) and from before to immediately after in the RET group (p<0.025).</p></caption><graphic xlink:href="jnnp-71-493-F2.jpg" alt-version="no" position="float" xlink:type="simple"></graphic></fig><fig id="F3" position="float"><label>Figure 3</label><caption><p>Mean SPL of the monologue immediately pretreatment (before), immediately post-treatment (immediately after), and 24 months after treatment (FU) in the LSVT® and RET groups. Differences from before to immediately after and from before to FU are significant in the LSVT ® group (p=0.000 and p=0.009, respectively) but not in the RET group.</p></caption><graphic xlink:href="jnnp-71-493-F3.jpg" alt-version="no" position="float" xlink:type="simple"></graphic></fig><fig id="F4" position="float"><label>Figure 4</label><caption><p>Mean STSD of reading the “rainbow passage” immediately pretreatment (before), immediately post-treatment (immediately after), and 24 months after treatment (FU) in the LSVT® and RET groups. Differences from before to immediately after and from before to FU are significant in the LSVT® group (p=0.000). The difference from before to immediately after is also statistically significant in the RET group (p=0.000). The difference from before to FU in the RET group is not significant.</p></caption><graphic xlink:href="jnnp-71-493-F4.jpg" alt-version="no" position="float" xlink:type="simple"></graphic></fig><fig id="F5" position="float"><label>Figure 5</label><caption><p>Mean STSD of the monologue immediately pretreatment (before), immediately post-treatment (immediately after), and 24 months after treatment (FU) in the LSVT® and RET groups. Differences from before to immediately after and from before to FU are significant in the LSVT ® group (p=0.019 and p=0.044, respectively) but not in the RET group.</p></caption><graphic xlink:href="jnnp-71-493-F5.jpg" alt-version="no" position="float" xlink:type="simple"></graphic></fig></floats-wrap></article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Intensive voice treatment (LSVT®) for patients with Parkinson's disease: a 2 year follow up</title></titleInfo><titleInfo type="alternative" lang="en" contentType="CDATA"><title>Intensive voice treatment (LSVT®) for patients with Parkinson's disease: a 2 year follow up</title></titleInfo><name type="personal"><namePart type="given">L O</namePart><namePart type="family">Ramig</namePart><affiliation></affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Sapir</namePart><affiliation></affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Countryman</namePart><affiliation></affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A A</namePart><namePart type="family">Pawlas</namePart><affiliation></affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C</namePart><namePart type="family">O'Brien</namePart><affiliation></affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Hoehn</namePart><affiliation></affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">L L</namePart><namePart type="family">Thompson</namePart><affiliation></affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="research-article"></genre><subject><genre>hwp-journal-coll</genre><topic>Drugs: CNS (not psychiatric)</topic></subject><subject><genre>hwp-journal-coll</genre><topic>Parkinson's disease</topic></subject><originInfo><publisher>BMJ Publishing Group Ltd</publisher><dateIssued encoding="w3cdtf">2001-10-01</dateIssued><dateCreated encoding="w3cdtf">2001-10-01</dateCreated><copyrightDate encoding="w3cdtf">2001</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType></physicalDescription><abstract>OBJECTIVES To assess long term (24 months) effects of the Lee Silverman voice treatment (LSVT®), a method designed to improve vocal function in patients with Parkinson's disease. METHODS Thirty three patients with idiopathic Parkinson's disease were stratified and randomly assigned to two treatment groups. One group received the LSVT®, which emphasises high phonatory-respiratory effort. The other group received respiratory therapy (RET), which emphasises high respiratory effort alone. Patients in both treatment groups sustained vowel phonation, read a passage, and produced a monologue under identical conditions before, immediately after, and 24 months after speech treatment. Change in vocal function was measured by means of acoustic analyses of voice loudness (measured as sound pressure level, or SPL) and inflection in voice fundamental frequency (measured in terms of semitone standard deviation, or STSD). RESULTS The LSVT® was significantly more effective than the RET in improving (increasing) SPL and STSD immediately post-treatment and maintaining those improvements at 2 year follow up. CONCLUSIONS The findings provide evidence for the efficacy of the LSVT® as well as the long term maintenance of these effects in the treatment of voice and speech disorders in patients with idiopathic Parkinson's disease.</abstract><subject><genre>Keywords</genre><topic>voice treatment</topic><topic>efficacy</topic><topic>Parkinson's disease</topic></subject><relatedItem type="host"><titleInfo><title>Journal of Neurology, Neurosurgery & Psychiatry</title></titleInfo><titleInfo type="abbreviated"><title>J Neurol Neurosurg Psychiatry</title></titleInfo><genre type="Journal">journal</genre><identifier type="ISSN">0022-3050</identifier><identifier type="eISSN">1468-330X</identifier><identifier type="PublisherID">jnnp</identifier><identifier type="PublisherID-hwp">jnnp</identifier><identifier type="PublisherID-nlm-ta">J Neurol Neurosurg Psychiatry</identifier><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>71</number></detail><detail type="issue"><caption>no.</caption><number>4</number></detail><extent unit="pages"><start>493</start></extent></part></relatedItem><identifier type="istex">5CB6FCB786207A62AA94D28C7721596D39781D38</identifier><identifier type="DOI">10.1136/jnnp.71.4.493</identifier><identifier type="href">jnnp-71-493.pdf</identifier><identifier type="PMID">11561033</identifier><identifier type="local">jnnp;71/4/493</identifier><accessCondition type="use and reproduction" contentType="copyright">Journal of Neurology, Neurosurgery, and Psychiatry</accessCondition><recordInfo><recordContentSource>BMJ</recordContentSource></recordInfo></mods></metadata><annexes><json:item><original>true</original><mimetype>image/jpeg</mimetype><extension>jpeg</extension><uri>https://api.istex.fr/document/5CB6FCB786207A62AA94D28C7721596D39781D38/annexes/jpeg</uri></json:item></annexes><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B95 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000B95 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:5CB6FCB786207A62AA94D28C7721596D39781D38
|texte= Intensive voice treatment (LSVT®) for patients with Parkinson's disease: a 2 year follow up
}}
| This area was generated with Dilib version V0.6.23. |  |